Cas:1017789-66-0 tert-butyl N-(1-methylazetidin-3-yl)carbamate manufacturer & supplier

We serve Chemical Name:tert-butyl N-(1-methylazetidin-3-yl)carbamate CAS:1017789-66-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

tert-butyl N-(1-methylazetidin-3-yl)carbamate

Chemical Name:tert-butyl N-(1-methylazetidin-3-yl)carbamate
CAS.NO:1017789-66-0
Synonyms:1-Methyl-3-N-Boc-amino-azetidine;(1-Methyl-azetidin-3-yl)-carbamic acid tert-butyl ester;S14-2668
Molecular Formula:C9H18N2O2
Molecular Weight:186.25100
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:41.57000
Exact Mass:186.13700
LogP:1.15390

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-Methyl-3-N-Boc-amino-azetidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,S14-2668 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Methyl-3-N-Boc-amino-azetidine Use and application,(1-Methyl-azetidin-3-yl)-carbamic acid tert-butyl ester technical grade,usp/ep/jp grade.


Related News: RELATED: With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO (7-oxo-1,2,5,7-tetrahydro-4H-furo[3,4-d][1,3]thiazin-2-yl)-tritylamino-acetic acid manufacturers GBS is a rare but potentially life-threatening disorder in which the body’s immune system attacks nerve cells. The condition has been associated with the use of other widely used vaccines, such as GlaxoSmithKline’s Shingrix. 1-chloro-2-(chloromethyl)-4-nitrobenzene suppliers Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries. N,N-Dimethyl-N’-phenylisobutyramidin vendor & factory In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis.,RELATED: With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO